627. Aggressive Lymphomas: Clinical and Epidemiological: Population data for Aggressive NHL Management
Daniel A. Ermann, Victoria A. Vardell, Harsh Shah, et al.
The data shows an improved OS. This applies both to node-only disease and within certain subgroups of EN disease when RT is used in addition to first-line chemotherapy. See abstract for more info.
Jordan Carter, Adam J. Olszewski, Tatyana A. Feldman, et al.
See abstract for more info
Andreas Kiesbye Øvlisen, Lasse H. Jakobsen, Kristian Hay Kragholm, et al.
NHL patients are at significantly higher risk for mental health problems compared to the general population. This is suggested by the prescribing data for psychotropic substances. See abstract for more info
Anita Kumar, Jason R. Westin, Stephen J. Schuster, et al.
A high proportion of 45 percent of clinical recurrences in asymptomatic patients is demonstrated radiographically. This emphasizes the value of surveillance CT imaging in DLBCL, especially in patients with advanced or high-risk disease. See abstract for more info
Freja Tang Severinsen, Laura Mors Haunstrup, Rasmus Kuhr Jensen, et al.
Patients who were not enrolled in a study had poorer survival even after adjusting for imbalances in age and disease risk category. See abstract for more info
Carmelo Carlo-Stella, Pier Luigi Luigi Zinzani, Murali Janakiram, et al.
In patients with R/R-DLBCL, Lonca + ibrutinib demonstrated encouraging antitumor activity at the dosages tested. The safety profile is manageable.